Crossmark

Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin

Crossref DOI link: https://doi.org/10.1007/s40261-018-0692-7

Published Online: 2018-08-31

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Duchin, Kenneth

Senaldi, Giorgio

Warren, Vance

Marbury, Thomas

Lasseter, Kenneth

Zahir, Hamim https://orcid.org/0000-0002-2501-5669
License Information

Text and Data Mining valid from 2018-08-31
More Information

Article History

First Online: 31 August 2018

Compliance with Ethical Standards

:

: This study was funded by Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.

: Thomas Marbury reports grants from the Orlando Clinical Research Center during the conduct of the study and is an equity owner of the Orlando Clinical Research Center. Giorgio Senaldi, Vance Warren, and Hamim Zahir were employees of Daiichi Sankyo at the time the study was conducted. Kenneth Duchin is a consultant to Daiichi Sankyo and has no other conflicts of interest to report. Kenneth Lasseter has no conflicts of interest that are directly relevant to the contents of this article.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: All subjects provided written informed consent prior to enrollment.